Probiodrug - Company & Market Research Reports

Probiodrug AG is a biopharmaceutical company focused on the development and commercialisation of new therapeutic products for the treatment of Alzheimer's disease. Headquartered in Halle, Germany, Probiodrug was founded in 1997 by Prof Dr. Hans-Ulrich Demuth and Dr. Konrad Glund and successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors / gliptins. Today, the company's lead product candidate is PQ912, an inhibitor of QC for Alzheimer animal models.

Alzheimer's Disease - Pipeline Review, H2 2018 - Product Thumbnail Image

Alzheimer's Disease - Pipeline Review, H2 2018

  • Drug Pipelines
  • 1333 Pages
From
From
Huntington Disease - Pipeline Review, H2 2017 - Product Thumbnail Image

Huntington Disease - Pipeline Review, H2 2017

  • Drug Pipelines
  • 287 Pages
From
Huntington Disease - Pipeline Review, H1 2017 - Product Thumbnail Image

Huntington Disease - Pipeline Review, H1 2017

  • Drug Pipelines
  • 299 Pages
From
From
From
From
  • 10 Results (Page 1 of 1)
Loading Indicator
adroll